Cited by 64Hematopoietic Stem Cell TransplantationNeutropenia and Cancer InfectionsBlood disorders and treatments

Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents.

van Os, Ronald, Robinson, Simon, Sheridan, Tara, Mislow, John M.K., Dawes, Donald, Mauch, Peter M.·1998·Blood

Abstract

Despite the increasing use of cytokines to circumvent the acute dose-limiting myelotoxicity of cancer treatment, little is known about the combined effects of cytotoxic agents and cytokines on the primitive stem cells responsible for long-term hematopoiesis. In an experimental model, we administered cytotoxic agents that have variable effects on primitive stem cells in C57BL/6 (B6)-mice. Mice received six every-other-week doses of cyclophosphamide (CY, 84 mg/kg), VP-16 (24 mg/kg) + cisplatinum (2.4 mg/kg), carboplatinum (50 mg/kg), chlorambucil (12 mg/kg), BCNU (13.2 mg/kg), or TBI (80 cGy). Granulocyte colony-stimulating factor (G-CSF; 250 microg/kg/day) was administered subcutaneously twice daily on days 3 to 6 after each dose of the cytotoxic agent. Comparison with animals receiving the cytotoxic agent alone was made to investigate the effects of G-CSF on long-term hematopoiesis. Hematopoiesis was measured 20 weeks after the last dose of the cytotoxic agent by assessment of peripheral blood counts, marrow cellularity, progenitor cell content (colony-forming units-spleen; CFU-S), and primitive stem cell number (long-term repopulating ability and day 28 and day 35 cobblestone area-forming cell [CAFC] frequencies). Exposure to cytotoxic agents alone resulted in a significant decrease in primitive stem cells (as measured by repopulating units [RU] and day 28 and day 35 CAFC content) in animals given carboplatinum, chlorambucil, BCNU, and TBI, but not in animals treated with cyclophosphamide or VP-16 and cisplatinum. The addition of G-CSF resulted in a significant decrease in stem cell content when compared with no G-CSF administration in animals treated with chlorambucil, BCNU, or TBI. Thus, G-CSF administered after repeated exposure to cytotoxic agents, appeared to damage the primitive stem cell compartment when used in combination with agents known to damage primitive stem cells. These results, although obtained in an experimental model, should raise concerns for the indiscriminate use of G-CSF in the clinic.

Integrity signals

Registry

Crossref · 10.1182/blood.v92.6.1950

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
van Os, R., Robinson, S., Sheridan, T., Mislow, J. M. K., Dawes, D., & Mauch, P. M.
Affiliations
  • From the Joint Center for Radiation Therapy, Department of Radiation Oncology, Harvard Medical School, Boston, MA.
  • Harvard University (US)
Venue
Blood
Published
1998-09-15
Volume
92
Issue
6
Pages
1950-1956
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W142692312
Cited by
64
References
47
Citations by year
2026: 2 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 1 · 2020: 1 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 1 · 2013: 3 · 2012: 2
FWCI
2.79
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Funders
  • Centers for Disease Control and Prevention (P50 HK54785-01)
  • National Cancer Institute (R01CA010941, R01-CA10941-26)
Topics
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Blood disorders and treatments
Keywords
granulocyte colony-stimulating factor, bone marrow-derived stem cells, myelosuppression, long-term hematopoiesis, cobblestone area-forming cells, CFU-S, cyclophosphamide, carboplatin, chlorambucil, BCNU, total body irradiation, hematopoietic progenitor cells, cytokine therapy
MeSH terms
Animals, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Cells, Cell Count, Cyclophosphamide, Drug Administration Schedule, Etoposide, Male, Mice, Inbred C57BL, Stem Cells, Granulocyte Colony-Stimulating Factor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review